ABL Bio is a privately held biotechnology company developing antibody therapeutics for immuno oncology and neurodegenerative disease.
ABL Bio, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ablbio” connections=”true” suffix=””]
ABL Bio is harnessing its BsAb (bispecific antibodies) expertise to develop next-generation BsAbs designed to maximize blood_
brain barrier penetrance and therapeutic efficacy. The most advanced molecule is ABL301, an ?-synuclein (SNCA)-targeting BsAb that penetrates the BBB via a receptor-mediated transcytosis (RMT) receptor and is in development for Parkinsons.
In July 2018, I-Mab Biopharma out-license to ABL Bio, the global rights excluding Greater China to I-Mabs bispecific antibodies (BsAb) of undisclosed target with licensing payments of approx. US$100 Mn in total, with US$2.5 Mn in upfront payment. Also the two companies agreed to co-develop three novel Immuno-oncology (I-O) BsAbs utilizing ABL Bios innovative BsAb platform. The companies will share the development costs as well as rights in China, South Korea and rest of the world in different configurations.
In Jun 2018, ABL Bio out license global commercial rights to ABL Bios pipeline of novel therapeutic antibodies to TRIGR Therapeutics.
These therapeutic antibodies include BBB penetrating BsAb (VEGF/undisclosed BBB target BsAb, undisclosed target/
undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb, 4-1BB/ undisclosed
target BsAb); and a monoclonal antibody against undisclosed target. Under the terms, TRIGR paid USD $4.3 Mn as upfront fee;
plus upto USD $550 Mn as research, regulatory and sales-based milestones to ABL Bio for the global rights .
In Jun 2018, ABL Bio completed $65 Mn in Series C financing led by by Alpen Route Asset Management, DS Asset Management, Hana Financial Investment and Quad Asset Management. Earlier, ABL raised aprox $30 Mn in three rounds of investments from Korea Investment Partners, DSC Investment and other institutional investors.